Immatics N.v. · NASDAQ:IMTX
Immatics — Investor Presentation (September 2020)
36 slides from Immatics's investor presentation, Sep 29, 2020
Slide 1: Immatics Corporate Presentation, October 2020
Immatics Corporate Presentation, October 2020 Exhibit 99.2
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation (“Presentation”) is provided by Immatics N.V. (“Immatics” or the “Company”) for informational purposes only. The information contained herein does not purport to be all-inclusive and Immatics nor any of its affiliates nor any of its or their control person
Slide 3: Key Elements to Build a Global Leader in TCR-based Immunotherapies
Key Elements to Build a Global Leader in TCR-based Immunotherapies Immatics is advancing a proprietary pipeline of Adoptive Cell Therapies (ACT) & TCR Bispecifics Four ACT programs in clinical development covering a broad range of solid cancers Two TCR Bispecifics programs with off-the-shelf availab
Slide 4: Developing Targeted Therapeutics to Patients with Solid Cancers
Developing Targeted Therapeutics to Patients with Solid Cancers urrent HEfficacy Checkpoint inhibitors Clinical benefit mainly in patients with tumors with high mutational burden minority of all cancers* CAR-T Clinical benefit mainly in patients with hematological indications minority of all cancers
Slide 5: pHLA Targets Identified on Human Cancer Cells by Our Technology Platform
pHLA Targets Identified on Human Cancer Cells by Our Technology Platform Are Building the Foundation for TCR-Based Therapies to Unlock Immunotherapies for Solid Cancers
Slide 6: Developing Two Distinct Targeted Treatment Modalities
Developing Two Distinct Targeted Treatment Modalities Addressing the Needs of Patients with Bulky & De-Bulked Tumors Adoptive Cell Therapy ACTengine® TCR Bispecifics TCER™
Slide 7: A Fully-owned Proprietary Pipeline of Clinical & Pre-Clinical Programs
A Fully-owned Proprietary Pipeline of 4 Clinical & 4 Pre-Clinical Programs Leveraging Immatics pHLA Targets in 2 Distinct Treatment Modalities Product Class Product Candidate Indications Preclinical Phase 1 Phase 2 Phase 3 Next expected Milestones Autologous TCR-T ACTengine® IMA201 (MAGEA4/8) Solid
Slide 8: Developing Programs with World-leading Industry Players
Developing 10 Programs with World-leading Industry Players Validating Immatics’ Unique Technologies and Expertise 2017 Bispecific Cancer Immunotherapies $30m upfront 2 Immatics targets 2018 Bispecific Cancer Immunotherapies $54m upfront 3 Immatics targets 2019 Adoptive Cell Therapies $75m upfront 3
Slide 9: Immatics – Delivering the Power of T cells to Cancer Patients
Immatics – Delivering the Power of T cells to Cancer Patients IDENTIFY True Targets and Right TCRs DELIVER Therapeutic Pipelines of ACT and TCR Bispecifics PIONEER Multi-Target Personalized Precision Immunotherapy Two Proprietary Technology Platforms as foundation for the next advance in immunothera
Slide 10: Discovery of True Cancer Targets – XPRESIDENT Technology Platform
Discovery of True Cancer Targets – XPRESIDENT® Technology Platform Prioritization of >200 pHLA Targets Covering All Target Classes >200 prioritized targets >400 million MS/MS spectra >20,000 experiments >8,000 peptides filed for patent >2,000 cancer & normal tissues analyzed by Quantitative MS Cance
Slide 11: Development of the Right TCR for Two Modalities – XCEPTOR
Development of the Right TCR for Two Modalities – ACT and Bispecifics By Our XCEPTOR™ Technology Platform TCR Bispecifics T cell engaging receptor (TCER™) Affinity-maturated natural TCR variable domains with nanomolar affinity and favorable specificity profile Highly potent TCR Bispecifics format wi
Slide 12: Platform Interaction Allows for Early De-selection of Cross-Reactive TCRs
Platform Interaction Allows for Early De-selection of Cross-Reactive TCRs ExDPIxxxY ESDPIVAQY Titin EPDPILDNY C19orf26 EVDPIRHYY MAGE B18 MAGE A3 EVDPIGHLY (target) Clinical fatalities have occurred in TCR-T trials using a titin cross-reactive TCR (published 2013) XPRESIDENT®-guided toxicity screeni
Slide 13: Immatics – Delivering the Power of T cells to Cancer Patients
Immatics – Delivering the Power of T cells to Cancer Patients IDENTIFY True Targets and Right TCRs DELIVER Therapeutic Pipelines of ACT and TCR Bispecifics PIONEER Multi-Target Personalized Precision Immunotherapy Two Proprietary Technology Platforms as foundation for the next advance in immunothera
Slide 14: Developing Two Distinct Targeted Treatment Modalities
Developing Two Distinct Targeted Treatment Modalities Addressing the Needs of Patients with Bulky & De-Bulked Tumors Adoptive Cell Therapy ACTengine® TCR Bispecifics TCER™
Slide 15: ACTengine – Engineered TCR-T Therapy
ACTengine® – Engineered TCR-T Therapy Autologous, Genetically Modified T cells Expressing a Novel TCR Leukapheresis 4 Immatics targets IMA201, 202, 203, 204 Cancer patient Biopsy: Biomarker profiling Individual T cell product against selected target Genetic engineering Pre-activation Transduction Ex
Slide 16: Optimized Manufacturing for Younger T cells & Timely Patient Infusion
Optimized Manufacturing for Younger T cells & Timely Patient Infusion Established cGMP Capacities to Advance Next-Generation Cell Manufacturing Developments Leukapheresis Infusion-Ready Manufacturing by Immatics Personnel for ongoing ACT programs Proprietary short manufacturing process designed to p
Slide 17: ACTengine Targets: Prevalence and Characteristics
NY-ESO-15 MAGEA4/A8 IMA201 MAGEA1 IMA202 PRAME IMA203 COL6A3 exon 6 IMA204 Naturally presented Yes1 Yes2 Yes2 Yes2 Yes2 Specificity class3 1 1 1 1 2 Number of pHLA copies per cell 10-504 100-1,0002 50-9002 100-1,0002 100-7002 Tumor types with significant prevalence Synovial sarcoma (80%) Melanoma (4
Slide 18: ACTengine - Initial Safety and Persistence of T cells
ACTengine® - Initial Safety and Persistence of T cells Initial Data from IMA201, IMA202 and IMA203 as of 1Q 2020 Studies Enrollment Status Products successfully manufactured for 10/10 patients First 4 patients treated across IMA201, IMA202 and IMA203 trials at lowest dose of dose escalation scheme (
Slide 19: ACTengine Targets: Prevalence and Characteristics
NY-ESO-15 MAGEA4/A8 IMA201 MAGEA1 IMA202 PRAME IMA203 COL6A3 exon 6 IMA204 Naturally presented Yes1 Yes2 Yes2 Yes2 Yes2 Specificity class3 1 1 1 1 2 Number of pHLA copies per cell 10-504 100-1,0002 50-9002 100-1,0002 100-7002 Tumor types with significant prevalence Synovial sarcoma (80%) Melanoma (4
Slide 20: ACTengine IMA204 – Disrupting the Tumor's Protective Microenvironment
ACTengine® IMA204 – Disrupting the Tumor’s Protective Microenvironment Immatics’ Novel Tumor Stroma Target COL6A3 Exon 6 Example of a Tumor Target in the same Ovarian Cancer sample Stroma Target (COL6A3 exon 6) in an Ovarian Cancer sample Stroma cells Tumor cells COL6A3 exon 6 is prevalently express
Slide 21: ACTengine IMA204 – Complete Tumor Eradication in vitro and in vivo
ACTengine® IMA204 – Complete Tumor Eradication in vitro and in vivo Two Affinity-enhanced TCR Candidates with High Avidity, Specificity and Potency for IMA204 Two affinity-enhanced TCRs with excellent pre-clinical properties in vitro and in vivo One of the candidates shows full functionality also in
Slide 22: ACTallo – Next Generation Off-the-shelf TCR-T Therapy
ACTallo® – Next Generation Off-the-shelf TCR-T Therapy Allogenic, Genetically Modified γδ T cells Expressing a Novel TCR HLA-A*02 positive γδ T cells Are abundant in the peripheral blood Show intrinsic anti-tumor activity Naturally infiltrate solid tumors and correlate with favorable prognosis Are H
Slide 23: ACTallo – Efficient Transduction & Robust Expansion of γδ T cells
ACTallo® – Efficient Transduction & Robust Expansion of γδ T cells 4-in-1 construct: TCRα + TCRβ + CD8α + CD8β CD8α Vβ8 40.6% CD8+ vβ8+ Proprietary lentiviral vector system Transducing γδ T cells with a single vector might significantly reduce costs and complexity Current processes have the potentia
Slide 24: Developing Two Distinct Targeted Treatment Modalities
Developing Two Distinct Targeted Treatment Modalities Addressing the Needs of Patients with Bulky & De-Bulked Tumors Adoptive Cell Therapy ACTengine® TCR Bispecifics TCER™
Slide 25: TCER – Immatics' TCR Bispecifics Mode of Action
TCER™ – Immatics’ TCR Bispecifics Mode of Action
Slide 26: TCER – Engineering an off-the-shelf Biologic
TCER™ – Engineering an off-the-shelf Biologic TCR Bispecifics T cell engaging receptor (TCER™) Affinity-maturated natural TCR variable domains with nanomolar affinity and favorable specificity profile XPRESIDENT®-guided similar peptide counterselection during maturation Highly potent TCR Bispecifics
Slide 27: TCER Preclinical Data: Specificity, Potency and Stability
Tumor Xenograft Mouse Model Distinguished Specificity Broad therapeutic window (≥ 1,000 – 10,000 fold) as defined by reactivity against tumor cells and healthy tissue cells Proprietary TCR Bispecifics Format TCER™ design confers superior potency and stability compared to multiple tested alternative
Slide 28: Immatics – Delivering the Power of T cells to Cancer Patients
Immatics – Delivering the Power of T cells to Cancer Patients IDENTIFY True Targets and Right TCRs DELIVER Therapeutic Pipelines of ACT and TCR Bispecifics PIONEER Multi-Target Personalized Precision Immunotherapy Two Proprietary Technology Platforms as foundation for the next advance in immunothera
Slide 29: ACTolog IMA101 Approach
ACTolog® IMA101 Approach Personalized multi-target T cell therapy using a warehouse approach Autologous T cells, Endogenous TCRs Clinical proof of concept previously delivered in melanoma by Cassian Yee (MD Anderson Cancer Center) with single target in combination with checkpoint inhibition [Chapuis
Slide 30: ACTolog IMA101 Safety and Persistence Results
12 patients treated (various solid tumor indications). Median duration of disease of the patients was 4 years (range 2-18 years) with a median of 6 previous rounds of treatment (range 2-12). ACTolog® IMA101 is well-tolerated to date with no changes to treatment regime required. The most common adver
Slide 31: Immatics' Multi-target TCR-T Strategy and Vision
Immatics’ Multi-target TCR-T Strategy and Vision Addressing Major Challenges in Immuno-oncology to Make a Therapeutic Difference IMA201-204 Warehouse ACTolog® 7 Immatics’ targets ACTengine® IMA201-204 1 target/ TCR per trial BLA filing of ACTengine® warehouse or single TCRs e.g. IMA204 stroma target
Slide 32: The Leadership Team
The Leadership Team Experienced Global Leadership Team Across Europe and the US Harpreet Singh Chief Executive Officer Carsten Reinhardt Chief Development Officer Rainer Kramer Chief Business Officer Cedrik Britten Chief Medical Officer Arnd Christ Chief Financial Officer Toni Weinschenk Chief Innov
Slide 33: Strong, Focused and Highly Integrated Trans-Atlantic Organization
Strong, Focused and Highly Integrated Trans-Atlantic Organization Senior Leadership, Business Development, Intellectual Property, Regulatory Affairs, Communications Senior Leadership, Research and Development (Adoptive Cell Therapy), CMC, Clinical Operations, Regulatory Affairs, QA/QC, HR, Investor
Slide 34: Continuously Growing IP Portfolio Protecting Proprietary Know-How
Continuously Growing IP Portfolio Protecting Proprietary Know-How Immatics’ Patent Estate – Territorial Coverage IP protection on >8000 cancer targets, TCRs and technology Immatics files patent applications in all major countries and regions >230 granted patents in the US >15 granted patents in Euro
Slide 35: Recent Achievements & Anticipated Upcoming News Flow
Recent Achievements & Anticipated Upcoming News Flow Significantly increased clinical footprint for our ACTengine® programs Additional clinical trial sites have been initiated in Germany and the US Green light by the German regulatory authority for the IMA202 and IMA203 studies Screening of patients
Slide 36: Thank you
DELIVERING THE POWER OF T CELLS TO CANCER PATIENTS Thank you www.immatics.com Jin] ¥ a6@ immatics